Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
J Clin Pharm Ther ; 43(5): 626-632, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29920710

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Moringa oleifera (MO) Lam (Moringaceae) is commonly used as food supplement and as medicine in most African countries where malaria is also endemic. Therefore, co-administration of MO with antimalarials is a possibility. This study investigated the effects of MO leaves powder on the pharmacokinetics of amodiaquine (AQ) in human subjects. METHODS: Twenty healthy volunteers were recruited for the 3-period study. In the first period, a single dose of AQ tablet (10 mg/kg) was administered orally after an overnight fast. After a 7-day washout period, AQ was co-administered with MO. For the third period, each subject took 3 g MO once daily for 7 days and on the 8th day, MO was co-administered with AQ. The plasma concentrations of amodiaquine and desethylamodiaquine (DEAQ) were simultaneously determined using a validated HPLC method. RESULTS AND DISCUSSION: The results showed a significant decrease (P = .037) in the Cmax of AQ after concurrent administration (CA) with MO, whereas after pretreatment (PT), there was a 32% decrease in the Cmax of AQ. For the metabolite, DEAQ, Cmax increased significantly (P = .006) by 79.36%, and Cmax in PT was significantly higher than (P = .001) that of the CA arm of the study. AUC of DEAQ increased significantly by 40.4% (P = .006) and by 188% (P = .001) after CA and PT, respectively. WHAT IS NEW AND CONCLUSION: The study established pharmacokinetic interaction between AQ and MO when given together or following a long period of ingestion of MO. This may have clinical implications for malaria therapy.


Subject(s)
Amodiaquine/pharmacokinetics , Moringa oleifera/adverse effects , Plant Leaves/adverse effects , Powders/adverse effects , Adult , Amodiaquine/analogs & derivatives , Antimalarials/pharmacokinetics , Female , Healthy Volunteers , Herb-Drug Interactions/physiology , Humans , Male , Tablets/pharmacokinetics , Young Adult
2.
J Clin Pharm Ther ; 41(5): 546-51, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27426203

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Imatinib mesylate is the first-line drug for the treatment of Philadelphia/bcr-abl positive chronic myeloid leukaemia (CML). It is known to be metabolized mostly by CYP3A4 and CYP3A5 isoforms while its efflux is mediated by the transporters ABCB1 and ABCG2. Genetic polymorphism of some of these enzymes and transporters have been linked with inter-individual variations in the pharmacokinetics of the drug. This study, therefore, investigated the influence of CYP3A5*3, ABCG2 421C>A and ABCB1 3435 C>T genetic polymorphism on the clinical outcome and steady-state trough plasma concentration (TPC) of imatinib in Nigerians with CML. METHODS: A total of 110 Nigerians with CML each of whom had been receiving a 400 mg daily dose of imatinib for at least 1 month were genotyped for CYP3A5*3, ABCG2 421C>A and ABCB1 3435 C>T. The TPC of all the patients were determined by a validated HPLC method and possible relationships between genotypes, age, clinical outcome, sex, TPC and ethnicity were analysed. RESULTS AND DISCUSSION: Subjects of TT genotype of ABCB1 C3435T had higher frequencies of complete haematological response (CHR), complete cytogenetic response (CCR) and major molecular response (MMR) but these were not statistically significant (P < 0·05). No genetic polymorphism in ABCG2 421C>A was observed. However, significant associations were observed between TPC and various genotypes in both CYP3A5*3 (P < 0·001) and ABCB1 C3435T (P < 0·001). The GG and TT genotypes in CYP3A5*3 and ABCB1 C3435T, respectively, were linked with higher TPC. WHAT IS NEW AND CONCLUSION: This is the first pharmacogenetics study of CML patients in the Nigerian population with ethnic differences in the distribution of ABCB1 C3435T. Genetic polymorphisms in CYP3A5*3 and ABCB1 C3435T are associated with TPC in CML patients in this population.


Subject(s)
Antineoplastic Agents/blood , Cytochrome P-450 CYP3A/genetics , Imatinib Mesylate/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , ATP Binding Cassette Transporter, Subfamily B/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Female , Genotype , Humans , Imatinib Mesylate/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Middle Aged , Nigeria , Pharmacogenetics/methods , Polymorphism, Genetic/genetics , Young Adult
3.
Afr J Med Med Sci ; 33(3): 185-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15819461

ABSTRACT

This study compared the absolute bioavailability of quinine sulphate as capsule and as tablet against the intravenous (i.v.) infusion of the drug in twelve male volunteers. Six of the volunteers received intravenous infusion over 4 h as well as the capsule formulation of the drug in a cross-over manner, while the other six received the tablet formulation. Blood samples were taken at predetermined time intervals and plasma analysed for quinine (QN) using reversed-phase HPLC method. QN was rapidly absorbed after the two oral formulations with average t(max) of 2.67 h for both capsule and tablet. The mean elimination half-life of QN from the i.v. and oral dosage forms varied between 10 and 13.5 hr and were not statistically different (P > 0.05). On the contrary, the maximum plasma concentration (C(max)) and area under the curve (AUC) from capsule were comparable to those from i.v. (P > 0.05), while these values were markedly higher than values from tablet formulation (P < 0.05). The therapeutic QN plasma levels were not achieved with the tablet formulation. The absolute bioavailability (F) were 73% (C.l., 53.3 - 92.4%) and 39 % (C.I., 21.7 - 56.6%) for the capsule and tablet respectively and the difference was significant (P < 0.05). The subtherapeutic levels obtained from the tablet form used in this study may cause treatment failure during malaria and caution should be taken when predictions are made from results obtained from different formulations of QN.


Subject(s)
Antimalarials/pharmacokinetics , Quinine/pharmacokinetics , Administration, Oral , Adolescent , Adult , Antimalarials/blood , Area Under Curve , Biological Availability , Capsules , Cross-Over Studies , Half-Life , Humans , Infusions, Intravenous , Male , Quinine/blood , Tablets
4.
Eur J Clin Pharmacol ; 58(8): 543-5, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12451432

ABSTRACT

OBJECTIVE: The genetic polymorphic metabolic oxidation of proguanil was investigated in 126 healthy, unrelated Nigerian subjects as an indication of the phenotypic status of CYP2C19 in Nigerians. METHODS: The proguanil oxidation capacity was determined using the 8-h urinary metabolic ratio of the parent drug and its metabolite (cycloguanil) after a single oral dose of 200 mg proguanil. RESULTS: The frequency distribution of the proguanil metabolic ratio ranged from 0.01 to 39.64 with a median of 1.38 in the 126 Nigerians. On the basis of the antimode value of 10 for the proguanil/cycloguanil ratio, the prevalence of poor metabolisers in this Nigerian population was estimated to be 4.8% (6 of 126), which is very similar to that of S-mephenytoin (4.3%) found in a previous study in Nigerians. The data also demonstrated enormous inter-individual differences in the urinary proguanil/cycloguanil ratios with poor metabolisers excreting, on average, only about 8% of the quantity of cycloguanil excreted by extensive metabolisers. CONCLUSION: The incidence of phenotypically poor metabolisers of proguanil in this Nigerian population is similar to those reported for Caucasian and other African populations but is much lower than those reported for Orientals. The study further supports previous studies that proguanil can be used as an alternative probe to phenotype for CYP2C19 activity.


Subject(s)
Antimalarials/metabolism , Polymorphism, Genetic , Proguanil/metabolism , Adolescent , Adult , Aryl Hydrocarbon Hydroxylases/genetics , Cytochrome P-450 CYP2C19 , Female , Humans , Male , Mixed Function Oxygenases/genetics , Nigeria , Oxidation-Reduction
5.
Pharm World Sci ; 20(3): 118-22, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9618735

ABSTRACT

The pharmacokinetics of quinine were studied in six Nigerian patients during acute uncomplicated falciparum malaria and convalescent periods. An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively. From the individual quinine plasma profiles the mean plasma concentration of quinine at the time of parasite clearance was estimated as 4.5 +/- 1.1 micrograms/ml. Plasma quinine levels during malaria rose rapidly reaching a peak around the second and third days and declining thereafter as patients improved clinically. In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence. The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg). The present data suggest that malaria parasites in African patients are still very sensitive to quinine and that the current dosage of quinine is effective for the treatment of acute falciparum malaria in African patients without augmenting therapy with any other drug such as tetracycline or sulphadoxine-pyrimethamine. It also confirms that malaria significantly alters the pharmacokinetics of quinine in humans.


Subject(s)
Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Quinine/pharmacokinetics , Acute Disease , Adolescent , Adult , Animals , Area Under Curve , Body Temperature/drug effects , Child , Female , Humans , Malaria, Falciparum/blood , Male , Nigeria , Quinine/administration & dosage , Treatment Outcome
6.
Ther Drug Monit ; 18(5): 624-6, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8885130

ABSTRACT

The possible occurrence of a kinetic interaction between cyclosporine A and glibenclamide was assessed by reviewing data of six posttransplant diabetic patients who received the two drugs concurrently. Coadministration of the two drugs resulted in a 57% increase in the steady-state plasma cyclosporine levels despite normal hepatic and renal functions in the patients. This elevation in cyclosporine level is possibly due to an interaction between the two drugs resulting from an inhibition of CYP3A4-mediated metabolism of cyclosporine by glibenclamide. This observation calls for a closer monitoring of cyclosporine plasma levels during concomitant administration of these two drugs in this group of patients.


Subject(s)
Cyclosporine/pharmacology , Diabetes Mellitus/drug therapy , Glyburide/pharmacology , Hypoglycemic Agents/pharmacology , Immunosuppressive Agents/pharmacology , Adult , Cyclosporine/administration & dosage , Cyclosporine/blood , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/metabolism , Diabetes Mellitus/etiology , Drug Interactions , Drug Therapy, Combination , Female , Glyburide/administration & dosage , Humans , Hypoglycemic Agents/administration & dosage , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Kidney Transplantation , Male , Middle Aged , Mixed Function Oxygenases/metabolism , Postoperative Complications/blood
7.
Eur J Drug Metab Pharmacokinet ; 21(3): 217-21, 1996.
Article in English | MEDLINE | ID: mdl-8980918

ABSTRACT

The pharmacokinetics and bioavailability of drotaverine was studied in 10 healthy volunteers after administration of single 80 mg oral and intravenous doses of the HCl salt of the drug, in a crossover fashion. Plasma and urine samples were analyzed for the unchanged drug by HPLC. The pharmacokinetic parameters, such as elimination half-life, plasma clearance, renal clearance and apparent volume of distribution, were not influenced by the route of drug administration. The drug was mainly eliminated by non-renal routes since renal clearance accounted for only 0.31 +/- 0.13% of the total plasma clearance. The absolute bioavailability was variable and ranged from 24.5-91% with a mean of 58.2 +/- 18.2% (mean +/- SD). It is suggested that the high variation in the bioavailability of drotaverine HCl after oral administration may result in significant interindividual differences in therapeutic response.


Subject(s)
Papaverine/analogs & derivatives , Parasympatholytics/pharmacokinetics , Administration, Oral , Adult , Biological Availability , Chromatography, High Pressure Liquid , Cross-Over Studies , Humans , Injections, Intravenous , Papaverine/pharmacokinetics
8.
Ther Drug Monit ; 18(1): 30-3, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8848817

ABSTRACT

The relationship between saliva and plasma levels of quinine was studied in four healthy volunteers. After a single oral dose of quinine sulfate (600 mg) to the volunteers, quinine was determined in both saliva and plasma simultaneously over a 48-h period by an ion pair reverse-phase high performance liquid chromatography method. The tmax (4.3 +/- 0.5 h) and elimination half-life (11.8 +/- 2.9 h) of quinine derived from saliva levels were comparable with those obtained from plasma levels (tmax = 2.8 +/- 0.2 h, t1/2 = 12.9 +/- 2.3 h). A significant correlation existed between the plasma and saliva concentrations of the drug (r = 0.93, n = 20, p < 0.001). The mean saliva/plasma quinine concentration ratio was 0.24 +/- 0.02. The results suggest that quinine is passively secreted into saliva and that saliva level determination may be useful as a noninvasive method in the evaluation of pharmacokinetic parameters and therapeutic drug monitoring of quinine.


Subject(s)
Antimalarials/blood , Antimalarials/pharmacokinetics , Quinine/blood , Quinine/pharmacokinetics , Saliva/metabolism , Adult , Chromatography, High Pressure Liquid , Half-Life , Humans , Male
9.
Drug Metab Dispos ; 22(5): 756-60, 1994.
Article in English | MEDLINE | ID: mdl-7835228

ABSTRACT

Metabolism of methoxyphenamine (MP) was conducted in vitro using commercially available microsomes prepared from human AHH-1 TK+/-cells in which CYP2D6 had been expressed. This study has confirmed the involvement of CYP2D6 in the metabolism of MP to O-desmethylmethoxyphenamine (ODMP) and 5-hydroxymethoxyphenamine (5HMP), but not to N-desmethylmethoxyphenamine. It has also revealed that CYP2D6 catalyzes the formation of another, hitherto unknown, ring-hydroxylated metabolite of MP, isomeric with 5HMP. The analytical procedure used to identify and quantify MP metabolites involved an acetylation procedure that had distinct advantages. MP and its basic and amphoteric metabolites were all converted to neutral products that were efficiently extracted into organic solvent. The acetylated products also had good chromatographic properties and provided mass spectra that were readily interpretable. MP metabolism studies were also conducted with CYP2D6 microsomes in the presence of quinidine and quinine. The former was the more potent inhibitor of CYP2D6-catalyzed oxidations of MP. Its inclusion resulted in complete inhibition of metabolism of MP to ODMP, 5HMP, and its novel isomer. This study shows that the in vitro use of human cytochrome P450 isozyme preparations in drug metabolism studies can aid in the identification of possible in vivo metabolites of these drugs in humans and can provide information on putative drug-drug interactions.


Subject(s)
Adrenergic beta-Agonists/metabolism , Cytochrome P-450 Enzyme System/metabolism , Methamphetamine/analogs & derivatives , Microsomes, Liver/enzymology , Mixed Function Oxygenases/metabolism , Acetylation , Biotransformation , Cells, Cultured , Chromatography, Gas , Cytochrome P-450 CYP2D6 , Cytochrome P-450 Enzyme Inhibitors , Gas Chromatography-Mass Spectrometry , Humans , Lymphocytes/metabolism , Methamphetamine/metabolism , Microsomes, Liver/drug effects , Mixed Function Oxygenases/antagonists & inhibitors , Quinidine/pharmacology , Quinine/pharmacology
10.
J Chromatogr ; 622(1): 93-7, 1993 Dec 08.
Article in English | MEDLINE | ID: mdl-8120119

ABSTRACT

A simple and sensitive HPLC method for the determination of drotaverine in human plasma and urine has been developed. Alkalinized plasma or urine was extracted with organic solvent and the basic components in the organic phase were back-extracted into 0.1 M HCl. An aliquot of the aqueous layer was injected onto the column and the eluent was monitored at 254 nm. Separation was performed on a C18-column with 0.02 M sodium dihydrogen phosphate-methanol (30:70, v/v) containing perchlorate ion at pH 3.2 as mobile phase. Drotaverine was well resolved from the plasma constituents and internal standard. An excellent linearity was observed between peak-height ratios and plasma concentrations and the intra- and inter-assay coefficients of variation were always < 10%. The lowest limit of detection (signal-to-noise ratio 3:1) was 6 ng/ml. The method is suitable for therapeutic monitoring and pharmacokinetic studies of drotaverine in humans as well as in animal models.


Subject(s)
Papaverine/analogs & derivatives , Sympatholytics/analysis , Chromatography, High Pressure Liquid/methods , Humans , Male , Papaverine/analysis , Papaverine/blood , Papaverine/urine , Regression Analysis , Spectrophotometry, Ultraviolet , Sympatholytics/blood , Sympatholytics/urine
11.
Res Commun Chem Pathol Pharmacol ; 82(1): 111-20, 1993 Oct.
Article in English | MEDLINE | ID: mdl-8272570

ABSTRACT

In vitro metabolism of the tricyclic antidepressant trimipramine using a commercial preparation of human CYP2D6 isozyme expressed in a human cell line is described. 2-Hydroxytrimipramine and a previously unreported metabolite, 2,10- or 2,11-dihydroxytrimipramine were isolated. Their structures were determined by gas chromatography/mass spectroscopy of underivatized and derivatized extracts. Acetylation of the new metabolite resulted in dehydration at C10 to give 10,11-dehydro-2-acetoxytrimipramine. No N-dealkylation of trimipramine was observed. Prior administration of quinidine produced a large reduction in the metabolic oxidation of trimipramine with CYP2D6 while prior administration of quinine had no effect. The use of this CYP2D6 isozyme preparation in vitro is of value in the identification of possible in vivo substrates for the human CYP2D6 isozyme.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Isoenzymes/metabolism , Mixed Function Oxygenases/metabolism , Trimipramine/metabolism , Cell Line , Cytochrome P-450 CYP2D6 , Gas Chromatography-Mass Spectrometry , Humans , Hydroxylation , Substrate Specificity , Trimipramine/analogs & derivatives , Trimipramine/isolation & purification
12.
J Chromatogr ; 616(1): 151-4, 1993 Jun 23.
Article in English | MEDLINE | ID: mdl-8376486

ABSTRACT

A new simple, selective and reproducible high-performance liquid chromatographic method for the determination of quinine in plasma, saliva and urine is described. The ion-pair method was carried out on a reversed-phase C18 column, using perchlorate ion as the counter ion and ultraviolet detection at 254 nm. Quinine was well resolved from its major metabolite, 3-hydroxyquinine, and the internal standard, primaquine. The limit of detection was 10 ng/ml and the recovery was greater than 90% from the three biological fluids.


Subject(s)
Quinine/analysis , Saliva/chemistry , Chromatography, High Pressure Liquid , Humans , Indicators and Reagents , Primaquine/analysis , Primaquine/blood , Primaquine/urine , Quinidine/analogs & derivatives , Quinidine/analysis , Quinidine/blood , Quinidine/urine , Quinine/blood , Quinine/urine , Spectrophotometry, Ultraviolet
13.
Xenobiotica ; 21(4): 447-50, 1991 Apr.
Article in English | MEDLINE | ID: mdl-1897244

ABSTRACT

1. The major metabolite of quinine in human urine, which is also the sole metabolite in human plasma and saliva, has been identified and characterized by chemical ionization mass spectrometry and 1H-n.m.r. spectrometry. 2. The mass spectrum showed that an oxygen atom is incorporated in the quinuclidine nucleus, and the exact position of the oxidation was established from the n.m.r. spectrum to be at the C-3 position.


Subject(s)
Quinidine/analogs & derivatives , Quinine/metabolism , Adult , Humans , Magnetic Resonance Spectroscopy , Male , Quinidine/urine
14.
Br J Clin Pharmacol ; 23(4): 473-6, 1987 Apr.
Article in English | MEDLINE | ID: mdl-3580253

ABSTRACT

The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in eleven lactating mothers following a single oral dose of chloroquine (600 mg base). The average milk to plasma concentration ratio at the 24th hour was 6.6 +/- 2.4 for chloroquine and 1.5 +/- 0.6 for desethylchloroquine in five of the volunteers. In five other volunteers the elimination half-life of chloroquine in milk was 8.8 +/- 4.7 days which was longer than that in saliva (3.9 +/- 1.0 days) from the same volunteers. The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. It is, therefore, suggested that it is safe for mothers to breastfeed their infants when undergoing treatment for malaria with chloroquine.


Subject(s)
Chloroquine/analogs & derivatives , Chloroquine/metabolism , Milk, Human/metabolism , Chromatography, High Pressure Liquid , Female , Half-Life , Humans , Hydrogen-Ion Concentration , Saliva/metabolism , Spectrophotometry, Ultraviolet
SELECTION OF CITATIONS
SEARCH DETAIL
...